Vicore Pharma Holding AB (publ) (FRA:6Y4)

Germany flag Germany · Delayed Price · Currency is EUR
0.9450
+0.0240 (2.61%)
At close: Nov 28, 2025
50.96%
Market Cap253.39M
Revenue (ttm)768.92K
Net Income (ttm)-38.39M
Shares Outn/a
EPS (ttm)-0.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open0.9450
Previous Close0.9210
Day's Range0.9450 - 0.9450
52-Week Range0.5210 - 1.1820
Betan/a
RSI50.60
Earnings DateFeb 27, 2026

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Employees 29
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6Y4
Full Company Profile

Financial Performance

Financial numbers in SEK Financial Statements

News

There is no news available yet.